Stock AEZS AETERNA ZENTARIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Aeterna Zentaris Inc.

Equities

AEZS

CA0079756007

End-of-day quote Toronto S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
11.57 CAD +0.17% Intraday chart for Aeterna Zentaris Inc. +4.33% +12.55%
05-17 Aeterna Zentaris Finalizes Some Details for Ceapro Merger MT
05-17 Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell
Top Premarket Gainers
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Aeterna Zentaris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones
AEterna Zentaris Reports Q1 Revenue of US$2.1 Million
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Aeterna Zentaris Inc. Provides Update on Macrilen(R) (Macimorelin) Reiterates Advancement of Pediatric DETECT Trial
Aeterna Zentaris Reports Q4 Net Loss of US$2.56 Per Share
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Aeterna Zentaris Reports Q3 Net Loss of US$0.70 Loss Per Basic Share
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Novo Nordisk Healthcare AG Exercises Right to Terminate the Amended Development and Commercialization License Agreement Previously Entered into Between Aeterna’s Wholly-Owned Subsidiary and Novo for Macrilen
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AEZS Stock
  4. News Aeterna Zentaris Inc.
  5. Other languages